Optimal infused CD34
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
31 Oct 2024
31 Oct 2024
Historique:
received:
27
08
2024
accepted:
08
10
2024
revised:
04
10
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
Autologous transplantation remains the standard of care for eligible multiple myeloma (MM) patients, yet optimal CD34
Identifiants
pubmed: 39482325
doi: 10.1038/s41408-024-01165-w
pii: 10.1038/s41408-024-01165-w
doi:
Substances chimiques
Antigens, CD34
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
189Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : Leukemia and Lymphoma Society (Leukemia & Lymphoma Society)
ID : SCOR-12206-17
Informations de copyright
© 2024. The Author(s).
Références
Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009;23:1904–12.
doi: 10.1038/leu.2009.127
pubmed: 19554029
Desikan KR, Tricot G, Munshi NC, Anaissie E, Spoon D, Fassas A, et al. Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol. 2001;112:242–7.
doi: 10.1046/j.1365-2141.2001.02498.x
pubmed: 11167811
Klaus J, Herrmann D, Breitkreutz I, Hegenbart U, Mazitschek U, Egerer G, et al. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Eur J Haematol. 2007;78:21–8.
doi: 10.1111/j.0902-4441.2006.t01-1-EJH2895.x
pubmed: 17042762
Shah N, Shi Q, Williams LA, Mendoza TR, Wang XS, Reuben JM, et al. Higher stem cell dose infusion after intensive chemotherapy does not improve symptom burden in older patients with multiple myeloma and amyloidosis. Biol Blood Marrow Transpl. 2016;22:226–31.
doi: 10.1016/j.bbmt.2015.07.036
Pavone V, Gaudio F, Console G, Vitolo U, Iacopino P, Guarini A, et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transpl. 2006;37:719–24.
doi: 10.1038/sj.bmt.1705298
Bolwell BJ, Pohlman B, Rybicki L, Sobecks R, Dean R, Curtis J, et al. Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transpl. 2007;40:437–41.
doi: 10.1038/sj.bmt.1705763
Yoon DH, Sohn BS, Jang G, Kim EK, Kang BW, Kim C, et al. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin’s lymphoma. Transfusion. 2009;49:1890–900.
doi: 10.1111/j.1537-2995.2009.02202.x
pubmed: 19453991
Blystad AK, Delabie J, Kvaløy S, Holte H, Vålerhaugen H, Ikonomou I, et al. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol. 2004;125:605–12.
doi: 10.1111/j.1365-2141.2004.04951.x
pubmed: 15147376
Aladağ KarakulakE, Demiroğlu H, Büyükaşik Y, Turgut M, Aksu S, Sayinalp N, et al. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation. Turk J Med Sci. 2020;50:1851–6.
doi: 10.3906/sag-2001-173
Partanen A, Turunen A, Silvennoinen R, Valtola J, Pyörälä M, Siitonen T, et al. Impact of the number of cryopreserved CD34(+) cells in the infused blood grafts on hematologic recovery and survival in myeloma patients after autologous stem cell transplantation: experience from the GOA study. J Clin Apher. 2023;38:33–44.
doi: 10.1002/jca.22022
pubmed: 36239392
Lebel E, Lajkosz K, Masih-Khan E, Reece D, Trudel S, Tiedemann R, et al. The impact of CD34(+) cell collection yields for autologous transplant on survival outcomes in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23:850–6.
doi: 10.1016/j.clml.2023.07.014
pubmed: 37689547
Mohan M, Szabo A, Patwari A, Esselmann J, Patel T, Bachu R, et al. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone Marrow Transplant. 2024;59:647–652.
Davis JA, Sborov DW, Wesson W, Julian K, Abdallah AO, McGuirk JP, et al. Efficacy and safety of CD34+ stem cell boost for delayed hematopoietic recovery after BCMA directed CAR T-cell therapy. Transpl Cell Ther. 2023;29:567–71.
doi: 10.1016/j.jtct.2023.05.012
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e46.
doi: 10.1016/S1470-2045(16)30206-6
pubmed: 27511158
Budczies J, Klauschen F, Sinn BV, Győrffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE. 2012;7:e51862.
doi: 10.1371/journal.pone.0051862
pubmed: 23251644
Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39:33–8.
doi: 10.1080/00031305.1985.10479383
Ho DE, Imai K, King G, Stuart EA. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Political Anal. 2007;15:199–236.
doi: 10.1093/pan/mpl013
Jantunen E, Turunen A, Varmavuo V, Partanen A. Impact of plerixafor use in the mobilization of blood grafts for autologous hematopoietic cell transplantation. Transfusion. 2024;64:742–50.
doi: 10.1111/trf.17755
pubmed: 38407504
Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995;86:3961–9.
doi: 10.1182/blood.V86.10.3961.bloodjournal86103961
pubmed: 7579367
Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol. 1995;13:2547–55.
doi: 10.1200/JCO.1995.13.10.2547
pubmed: 7595706
Raschle J, Ratschiller D, Mans S, Mueller BU, Pabst T. High levels of circulating CD34+ cells at autologous stem cell collection are associated with favourable prognosis in multiple myeloma. Br J Cancer. 2011;105:970–4.
doi: 10.1038/bjc.2011.329
pubmed: 21878938
Brioli A, Perrone G, Patriarca F, Pezzi A, Nobile F, Ballerini F, et al. Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. Bone Marrow Transpl. 2015;50:673–8.
doi: 10.1038/bmt.2014.322
Kakihana K, Ohashi K, Akiyama H, Sakamaki H. Correlation between survival and number of mobilized CD34+ cells in patients with multiple myeloma or Waldenström macroglobulinemia. Pathol Oncol Res. 2010;16:583–7.
doi: 10.1007/s12253-009-9238-x
pubmed: 20066576
Vogel W, Kopp HG, Kanz L, Einsele H. Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. J Cancer Res Clin Oncol. 2005;131:214–8.
doi: 10.1007/s00432-004-0635-y
pubmed: 15616828
Kopp HG, Yildirim S, Weisel KC, Kanz L, Vogel W. Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma. J Cancer Res Clin Oncol. 2009;135:637–42.
doi: 10.1007/s00432-008-0499-7
pubmed: 18941780
Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, et al. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J. 2023;13:68.
doi: 10.1038/s41408-023-00842-6
pubmed: 37137874
Lee SE, Lim JY, Kim TW, Ryu DB, Park SS, Jeon YW, et al. Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation. J Immunother Cancer. 2019;7:35.
doi: 10.1186/s40425-018-0491-y
pubmed: 30732646
Lim JY, Kim TW, Ryu DB, Park SS, Lee SE, Kim BS, et al. Myeloma-secreted galectin-1 potently interacts with CD304 on monocytic myeloid-derived suppressor cells. Cancer Immunol Res. 2021;9:503–13.
doi: 10.1158/2326-6066.CIR-20-0663
pubmed: 33771821
Tan CR, Derkach A, Nemirovsky D, Ciardiello A, Diamond B, Hultcrantz M, et al. Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma. Blood Cancer J. 2023;13:112.
doi: 10.1038/s41408-023-00882-y
pubmed: 37491332
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390:301–13.
doi: 10.1056/NEJMoa2312054
pubmed: 38084760
Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936–45.
doi: 10.1182/blood.2020005288
pubmed: 32325490
Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394:29–38.
doi: 10.1016/S0140-6736(19)31240-1
pubmed: 31171419
Lemonakis K, Tatting L, Lisak M, Carlson K, Crafoord J, Blimark CH, et al. Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients. Haematologica. 2023;108:610–4.
doi: 10.3324/haematol.2022.281610
pubmed: 36200424
Hulin C, Offner F, Moreau P, Roussel M, Belhadj K, Benboubker L, et al. Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study. Haematologica. 2021;106:2257–60.
doi: 10.3324/haematol.2020.261842
pubmed: 33657786
De Tena PS, Bailen R, Oarbeascoa G, Gomez-Centurion I, Perez-Corral A, Carbonell D, et al. Allogeneic CD34-selected stem cell boost as salvage treatment of life-threatening infection and severe cytopenias after CAR-T cell therapy. Transfusion. 2022;62:2143–7.
doi: 10.1111/trf.17071
pubmed: 35986653
Mullanfiroze K, Lazareva A, Chu J, Williams L, Burridge S, Silva J, et al. CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy. Blood Adv. 2022;6:4715–8.
doi: 10.1182/bloodadvances.2022007572
pubmed: 35790110